BPC-157: what the evidence actually says in 2026

Since BPC is pretty much the backbone of this board, here is where the actual data stands without the hype. What we have documented: - Decades of rodent work, mostly Achilles transection and tendon-to-bone models. Consistent hits across the board: better load to failure, higher stiffness, solid histology. - In vitro tendon fibroblast data showing faster migration, cell survival under strain, and GH receptor upregulation. - A legit mechanism: VEGFR2-driven angiogenesis targeting the hypovascular environment that makes tendons take months to heal. Where the real gaps lie: - Solid PK profiles for sub-q or oral protocols people actually run. - Accurate dose translation from animal models down to standard human pins. - The 2026 controlled study currently enrolling is for acute hamstring strains, not chronic tendinopathy. The mechanism is solid and the tissue data is impressive, but scaling it to an n=1 cycle requires realistic expectations and proper PT load. Ignoring the mechanism is stupid, but expecting a magic pin without doing the work is just as dumb.